Next-generation nutraceuticals are on the rise, and opportunities to use enzymes supporting human health are expanding rapidly. The common hurdle is that the human gastrointestinal tract is not particularly enzyme-friendly, making it difficult to use many enzymes directly as oral nutraceutical ingredients. Low pH conditions in the stomach and digestive proteases can quickly abolish enzyme stability and activity.

Aminoverse helps overcome these challenges with dedicated assays that mimic gastrointestinal conditions and the digestive process. Combined with enzyme engineering expertise, this enables the development of new enzyme variants with improved pH tolerance and protease resistance while maintaining functional performance.

To accelerate development, Aminoverse applies AI-powered fitness landscaping by combining wet- lab screening data covering thousands of data points with predictive sequence analysis to identify the most promising mutation targets for enhanced gastrointestinal stability.

For a customer developing an enzyme-based nutraceutical, Aminoverse delivered a targeted optimization strategy:

• Gastrointestinal simulation assays revealed critical stability losses under gastric conditions
• AI-powered fitness landscaping identified mutation sites linked to protease resistance
• Engineered variants showed improved activity retention at low pH
• The optimized enzyme advanced toward market-ready development and FDA filing